Mark Geyer is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1275 York Ave
New York, NY 100656007
Telephone
212-639-2000Provider last certified this registry record 8 May 2020.
Clinical trials
- A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
Sponsor: Memorial Sloan Kettering Cancer Center
- Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20252 payments
- Amgen Inc.Program year20253 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20245 payments$10,334openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Development of chimeric antigen receptor T cells targeting cell surface U5 snRNP for the treatment of acute myeloid leukemia
Sloan-Kettering Inst Can Research
FY2026$402,600R01CA291796 - Development of chimeric antigen receptor T cells targeting cell surface U5 snRNP for the treatment of acute myeloid leukemia
Sloan-Kettering Inst Can Research
FY2025$402,600R01CA291796 - Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
Actinium Pharmaceuticals, Inc.
FY2024$865,308R42CA254685
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”